| 1 |
34461182 | Sunitinib increases the cancer stem cells and vasculogenic mimicry formation via modulating the lncRNA-ECVSR/ERβ/Hif2-α signaling. | 2022 Jan 1 |
2 |
| 2 |
33799686 | Prolyl Hydroxylase 3 Knockdown Accelerates VHL-Mutant Kidney Cancer Growth In Vivo. | 2021 Mar 11 |
1 |
| 3 |
31268155 | Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment. | 2019 Aug |
1 |
| 4 |
29095068 | Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma. | 2018 Apr |
1 |
| 5 |
30267660 | RCAN1.4 acts as a suppressor of cancer progression and sunitinib resistance in clear cell renal cell carcinoma. | 2018 Nov 15 |
1 |
| 6 |
30369518 | Interleukin-6 induces drug resistance in renal cell carcinoma. | 2018 Dec 8 |
1 |
| 7 |
28217462 | The therapeutic potential of HIF-2 antagonism in renal cell carcinoma. | 2017 Feb |
1 |
| 8 |
28572533 | HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1α and HIF-2α balance in renal cell carcinoma. | 2017 Jul 25 |
3 |
| 9 |
28903416 | Overriding TKI resistance of renal cell carcinoma by combination therapy with IL-6 receptor blockade. | 2017 Aug 15 |
1 |
| 10 |
27488093 | Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer. | 2016 Aug 4 |
1 |
| 11 |
23788753 | Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma. | 2013 Sep |
1 |
| 12 |
19435875 | Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment. | 2009 May |
2 |